Anthony Clay, DO
Cardiovascular Disease · Newark, DENPI 1649202573
Payments from drug & device makers
Across 292 payments — averaging $7900.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1.7M
- GE HealthCare$410K
- Kowa Research Institute, Inc.$108K
- AstraZeneca$26K
- Sanofi-aventis U.S. LLC$7K
- Novartis$6K
- plus $8K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 46 | $1,742,355 |
| GE HealthCare | 33 | $410,226 |
| Kowa Research Institute, Inc. | 36 | $107,901 |
| AstraZeneca | 44 | $25,934 |
| Sanofi-aventis U.S. LLC | 14 | $6,803 |
| Novartis | 17 | $6,209 |
| Boehringer Ingelheim | 3 | $5,245 |
| Pfizer | 31 | $796 |
| Akcea Therapeutics, Inc. | 8 | $288 |
| E.r. Squibb & Sons, L.L.C. | 15 | $268 |
| Johnson & Johnson | 11 | $246 |
| Merck | 2 | $194 |
| Amarin Pharma, Inc. | 10 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $79 |
| Esperion Therapeutics, Inc. | 5 | $70 |
| Lundbeck LLC | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Amgen | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 2 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Medtronic | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Gilead | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$2,307,005 in reported general payments places this provider in the 95th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Newark
- William WeintraubNewark$1.3M
- Sourin BanerjiNewark$131K
- Anthony AlfieriNewark$80K
- James HopkinsNewark$79K
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Ashish ParikhNewark$29K
- Michael StillabowerNewark$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.